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Abstract
Birthweight for gestational age (BW/GA) has been associated with risk of adverse health
outcomes. Biological indices of pregnancy complications, maternal mid-pregnancy serum
biomarkers, and placental pathology may shed light on these associations, but at present, they are
most often examined as single entities and offer little insight about overlap. Additionally, these
indices are typically assessed in relation to the extremes of the BW/GA distribution, leaving open
the question of how they relate to the entire BW/GA distribution. Addressing issues such as these
may help elucidate why postnatal health outcomes vary across the BW/GA continuum.
In this study, we focused on a subset of women who participated in the Pregnancy Outcomes and
Community Health (POUCH) study (N=1371). We examined BW/GA (i.e., gestational age and
sex-referenced z-scores) in relation to obstetric complications, second trimester maternal serum
screening results, and histologic evidence of placental pathology along with maternal
demographics, anthropometrics, and substance use. In adjusted models, mean reductions in BW/
GA z-scores were associated with preeclampsia (β= −.70, 95%CI −1.04, −.36), high maternal
serum alpha fetoprotein (MSAFP: β= −.28, 95%CI −.43, −.13), unconjugated estriol (uE3: β= −.
31 per .5 MoM decrease, 95%CI −.41, −.21), and high levels of maternal obstructive vascular
pathology in the placenta (MV-O: β= −.46, 95%CI −.67, −.25). Findings were similar when
preterm infants, SGA, or LGA infants were removed. Future research is needed to examine how
the factors studied here might directly mediate or mark risk when evaluating associations between
BW/GA and postnatal health outcomes.
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Birthweight for gestational age (BW/GA) has been associated with numerous health
outcomes including risk of cardiovascular disease and diabetes, low IQ, and
psychopathology.1-4 Such findings are often interpreted within the framework of the
developmental origins of adult health and disease hypothesis (DOHaD), which postulates
that deleterious influences during sensitive periods (e.g., prenatal period) have long-lasting
effects on later development and health. Deleterious influences in the prenatal period are
commonly inferred from reductions in BW/GA continuum and are not limited to those born
small-for-gestational age (SGA) 5,6 or preterm.4,7
Ideally, investigators should turn their attention to pregnancy-related mediators and markers
of BW/GA that may more accurately identify and specify future health risk related to the in-
utero environment.1,8 Challenges include selecting relevant mediators/markers to consider
and comprehensive modeling to detect overlap. The human and animal literatures have
focused heavily on the role of maternal malnutrition and stress in explaining associations
between BW/GA and postnatal health outcomes, 9-11 while the role of other factors
associated with pregnancy health have received comparatively less attention. In addition,
clinical scenarios (e.g,. hypertensive disorders, gestational diabetes), biomarkers (e.g.,
maternal serum alpha fetoprotein), and evidence of placental pathology have been studied
most often as separate entities and in relation to BW/GA at the extremes of the
distribution. 12-1718-20 Yet, links between BW/GA and postnatal health outcomes span the
BW/GA continuum, suggesting that mediators/markers of the in-utero environment should
be similarly evaluated across the full distribution of BW/GA.
In this hypothesis-generating investigation, we used data from the Pregnancy Outcomes and
Community Health (POUCH) Study to examine associations between biological indicators
of the in-utero environment and BW/GA. These data are unique in that they bring together
commonly-studied factors associated with BW/GA (demographics, anthropometrics,
substance use, clinical-level diagnosis of pregnancy complications) and biologic measures
considered in separate studies. The selection of measures was guided by evidence linking
particular obstetric complications with BW/GA (e.g., preeclampsia, gestational diabetes),
the wide availability of maternal serum biomarkers used in routine pregnancy health
screening (i.e., high maternal serum alpha-fetoprotein, beta human chorionic gonadotropin,
unconjugated estriol),18,21,22 and an ever-growing appreciation for the role of placental
processes in supporting intrauterine growth.23-25 Our goals were to evaluate: 1) associations
between these biological indicators of pathology and BW/GA in a series of adjusted models,
and 2) whether any observed associations remained following the removal of preterm,
small-, or large-for-gestational age infants.
Methods
Participants
The POUCH Study, designed to examine etiological pathways leading to premature
delivery, enrolled 3019 women between 15 and 27 weeks of gestation from 52 prenatal
clinics in five Michigan communities.26 Eligibility criteria included English proficiency and
a singleton pregnancy with no known birth defects, chromosomal anomalies, or preexisting
diabetes; data reflect one pregnancy per participant. All women exhibiting maternal serum
alpha-fetoprotein (MSAFP) ≥ 2.0 multiples of the median (MoM) were invited to participate
in the study (7% of the cohort), and women with MSAFP <2.0 MoM were stratified by race/
ethnicity and sampled into the cohort. For a subset oversampled for African-American race,
high MSAFP, and preterm delivery, hereafter referred to as the subcohort (N=1371), in-
depth medical record abstraction was performed and placental samples were collected for
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later gross and histological examination. This sampling scheme was employed to maximize
resources when investigating at-risk subgroups,26 but use of sampling weights in analyses
produces results that reflect the entire cohort. All subcohort women were eligible for
inclusion in the present analysis, 1122 (81%) of whom had placental samples evaluated to
date. This study was approved by the Institutional Review Boards of Michigan State
University and all participating medical centers.
Measures
Obstetric Complications—Evidence of gestational diabetes (GDM), hypertensive
disorders (i.e., chronic hypertension (CH), gestational hypertension (GH), preeclampsia
(PE)), and placental abruption (PA) was abstracted from medical charts by trained staff
nurses. A team of clinicians and the principal investigator reviewed this evidence and
applied established criteria to assign the diagnostic categories, which included: GDM (failed
3-hour glucose tolerance test, failed glucose screen (> 190 mg/dl) accompanied by a fasting
glucose > 95 mg/dl, or explicit diagnosis in the medical records,27 CH (diastolic blood
pressure (DBP) > 90 or systolic blood pressure (SBP) > 140 on at least two occasions prior
to 20 weeks, medical record diagnosis, or use of hypertension medication), GH (no CH,
DBP > 90 or SBP > 140 on at least two occasions after 20 weeks), and PE (same criteria as
GH plus evidence of proteinuria),28-30 and PA (documented signs/symptoms of PA (e.g.,
significant bleeding not attributable to dilation) or retroplacental hematoma visualized on
prenatal ultrasound).31
Maternal Mid-Pregnancy Serum Biomarkers—MSAFP, unconjugated estriol (uE3),
and beta human chorionic gonadotropin (bHCG) levels were abstracted from medical
records, which were calculated as multiples of the median (MoM) adjusted for maternal
race, weight, and gestational age at sampling by the laboratory. Because the POUCH Study
oversampled women with MSAFP at ≥ 2.0 MoM, this value was used to dichotomize
women according to this same threshold, whereas levels of uE3 and bHCG were allowed to
vary continuously.
Placental Pathology—Placentas were obtained from 88% of the subcohort, and 92% of
these have been evaluated to date by the study pathologist who was blind to all clinical
circumstances surrounding delivery. Seven samples (five from the placental disc, two from
the membrane roll) were examined per placenta. Microscopic evidence of vascular
pathology was evaluated and grouped into five constructs which have been detailed
elsewhere.32 Briefly, these include: Maternal Vascular–Obstructive (MV-O) (e.g., decidual
vessel atherosis), Maternal Vascular–Developmental (MV-D) (e.g., abnormal/incomplete
conversion of the uterine spiral arteries), Maternal Vascular–Disturbance of Integrity (MV-I)
(e.g., retroplacental hemorrhage and decidual bleeding), Fetal Vascular–Obstructive (FV-O)
(e.g., thromboses), and Fetal Vascular–Disturbance of Integrity (FV-I) (e.g., fetal to
maternal hemorrhage).32 Scores for each of the five constructs, assigned on the distribution
of findings in term, normal MSAFP deliveries, were dichotomized at approximately the top
quintile to describe high and not high levels of vascular pathology.32
Placentas were also examined for evidence of histologic chorioamninoitis (HCA) according
to a grading and staging scheme described elsewhere.33 Evidence of inflammation was
described as none, mild, or severe, based on the concentration and location of
polymorphonuclear leukocytes (PMNL) and presence of necrotizing inflammation or PMNL
karyorrhexis.
Birthweight for gestational age (BW/GA)—Sex- and gestational-age referenced norms
were used to calculate birthweight for gestational age z-scores (BW/GAz), using
Talge et al. Page 3










birthweight, gestational age, and sex information abstracted from the participants’ medical
records.34 Gestational age was estimated using last menstrual period unless it was
unavailable or differed from the ultrasound estimate (at < 25 weeks) by more than two
weeks. In these cases (20% of the subcohort), the ultrasound-based estimate was employed
in data analysis. Infants were identified as small- or large-for-gestational-age using estimates
corresponding to the 10th and 90th percentiles, respectively.34
Additional Variables—At POUCH Study enrollment, maternal self-reports of race (non-
Hispanic white, black), parity (primiparous, multiparous), education (< 12, = 12, > 12
years), Medicaid assistance, age (< 20, 20-30, ≥ 30 years), height, and pre-pregnancy weight
were obtained along with their self-reported use of tobacco, alcohol, and illicit drugs
(marijuana, heroin, cocaine/crack, methamphetamines) during the index pregnancy. All
variables were analyzed categorically, except height which was analyzed continuously.
Maternal height and pre-pregnancy weight were used to calculate body mass index (BMI)
(kg/m2).
Statistical Analysis—To investigate associations among the factors listed above and BW/
GAz, general linear models (GLMs) were performed. All analyses, both unadjusted and
adjusted, were weighted for the oversampling of high MSAFP in the POUCH cohort and
oversampling of high MSAFP, African-American race, and preterm delivery in the
subcohort using PROC SURVEYREG (SAS 9.1).
We first examined associations among maternal demographics, anthropometrics, substance
use, and BW/GAz to identify a base model of covariates. Characteristics associated with
BW/GAz (p≤.10 or change in remaining estimates by ≥ 10%) were carried forward and
compared to each set of obstetric complication indices separately. Using the same criteria,
items from each of these analyses were entered into a single GLM to examine the extent to
which each was associated with BW/GAz after adjusting for the others. This final model
was repeated following the removal of preterm (< 37 weeks’ gestation), small-for-
gestational age (SGA) or large-for-gestational age (LGA) infants to examine if these groups
partially or fully accounted for any findings that were observed. The variable inflation factor
(VIF) was < 10 for every variable in every analysis, suggesting that multicollinearity did not
jeopardize the validity of the model estimates.
Results
In the POUCH subcohort, 25% self-identified as African American, 51% had 12 or fewer
years of education, 49% received Medicaid, and 47% exhibited pre-pregnancy BMIs in the
recommended range. Approximately 20% of women reported using tobacco, alcohol, or
illicit drugs at some point during their pregnancy prior to enrollment; additionally, 10% of
women had hypertensive disorders, 5% had GDM, and 1% experienced placental abruption.
Approximately 10-39% of placentas exhibited high levels of a particular vascular pathology
construct; 53% and 9% had evidence of mild and severe HCA, respectively (weighted
percents; Table 1).
Though not the focus of this study, we found that all maternal demographic, anthropometric,
and substance use variables were significantly associated with BW/GAz in their expected
directions (e.g., tobacco use, shorter height, lower BMI, lower education were associated
with lower BW/GAz). Table 2 presents the unadjusted associations between the main study
variables and BW/GAz; βs for categorical and continuous variables represent mean
differences and slopes, respectively. BW/GAz was related to PE (β= −.63, 95% CI −.95, −.
38), GDM (β=.62, 95% CI .23, 1.00) and two maternal serum biomarkers (high MSAFP: β=
−.24, 95% CI −.39, −.10; uE3 (per .5 MoM decrease): β= −.29, 95% CI −.39, −.19). Among
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women with available placental data, high MV-O and presence of severe HCA were
associated with a .62 and .33 mean decrease in BW/GAz, respectively.
In adjusted GLMs, all demographic, anthropometric, and substance use variables remained
significantly associated with BW/GAz, except for alcohol and illicit drug use. As a result,
these two variables were dropped from subsequent analyses, and those that remained
comprised a base model to which the remaining sets of variables were separately compared.
For obstetric complications, PE was associated with a decrease in BW/GAz (β= −.68, 95%
CI −1.05, −.32) and GDM was associated with an increase in BW/GAz (β=.48, 95%CI .11, .
84). For maternal serum biomarkers, high MSAFP and lower levels of uE3 remained
associated with decreases in BW/GAz (MSAFP: β= −.31, 95% CI −.46, −.15; uE3 (per .5
MoM decrease): β = −.31, 95% CI −.41, −.21). Among the placental pathology constructs,
only high MV-O remained significantly associated with decreases in BW/GAz (MV-O: β=
−.45, 95% CI −.67, −.24). Associations between severe HCA and BW/GAz were attenuated
and dropped below significance thresholds (β= −.14, 95%CI −.37, .01).
Because they were associated with BW/GAz in the above adjusted analyses, PE, GDM,
MSAFP, uE3, and MV-O were entered into a simultaneous GLM with the base model to
evaluate whether they retained their association with BW/GAz (Table 3). With the exception
of GDM, results indicated that they did and that the model accounted for 25% of the
variance in BW/GAz. The adjusted βs for biological indices approximated or exceeded those
for demographics, anthropometrics, or substance use (e.g., tobacco use: β = −.43, 95%CI) in
relation to BW/GAz.
The BW/GAz associations with PE, MSAFP, uE3, and MV-O persisted and were minimally
affected following the removal of infants born preterm (N=335), and were slightly
attenuated after removal of infants born SGA or LGA (Tables 3 and 4). All models
accounted for 19-27% of BW/GAz depending upon whether preterms, SGAs, and LGAs
were excluded.
Discussion
We evaluated whether BW/GA, which has been associated with many postnatal health
outcomes, was related to maternal serum biomarkers and placental pathology after other
known influences on growth were taken into account (e.g., maternal demographics,
anthropometrics, substance use). Our findings suggest that beyond these influences and
clinical-level diagnosis of obstetric complications, high MSAFP, lower levels of uE3, and
high levels of maternal obstructive vascular pathology were independently and robustly
associated with reductions in BW/GA. These findings were maintained irrespective of
whether preterms, SGAs or LGAs were excluded from the analysis, suggesting that factors
identified in our analyses are associated with reductions across the BW/GA distribution.
Though originally developed as a non-invasive screen for aneuploidy and other congenital
anomalies, studies suggest that even in the absence of these conditions, maternal serum
biomarkers are associated with aspects of maternal and fetal health (e.g., intrauterine growth
restriction) 18,21 and placental functioning.35 Of the biomarkers traditionally included in the
“triple screen,” high MSAFP and low uE3 have been the most consistently associated with
reductions in fetal growth and birthweight.19,22,36,37 The present study not only replicates
these findings, but extends them by examining their contribution to BW/GA beyond other
indices of pregnancy health (e.g., placental pathology).
The mechanisms underlying high MSAFP in the absence of neural tube defects or ventral
wall abnormalities are unclear. One hypothesis is that high MSAFP is a marker for
disturbances to the maternal-fetal interface, reflecting the leakage of AFP from the fetal
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circulation and amniotic fluid into the maternal bloodstream;18 previous studies have linked
unexplained high MSAFP with aspects of placental pathology.35 While high levels of
disruption to fetal vessel integrity (FV-I) were unrelated to birthweight z-scores in our study,
this may be because the “high” cutpoint for FV-I was constrained by our sample distribution
and captured the upper 39%. MSAFP may be a more specific measure of disturbances to
FV-I since its clinical cutpoint of 2.0 MoM applies to only 3-5% of screened populations.
Independent of high MSAFP, lower levels of uE3 were also associated with decreases in
BW/GA. uE3 has been interpreted as an indicator of fetal well-being, given that by the
second trimester, nearly 90% of circulating maternal serum estriol concentration is derived
from the substrate dehydroepiandrosterone sulfate (DHEA-S) produced by the fetal adrenals
(DHEA-S is converted to androgens and aromatized by placental sulfatases to produce
estriol).18 Low levels of uE3 can thus reflect decreases in fetal production of DHEA-S or
placental sulfatase activity.38,39 However, it is unclear what specific aspect of fetal
physiological functioning low concentrations of DHEA-S might reflect (e.g., reduced
adrenal sensitivity, decreased central stimulation), whether it is a proxy for less than optimal
fetal organ function, or whether it directly influences growth through interactions with other
hormones.40 Additionally, a constitutionally smaller fetus might secrete lower amounts of
DHEA-S as a function of its smaller size. We do not believe this explains our findings
because women who self-identified as Asian, a population often described as delivering
constitutionally-smaller babies,14 exhibited higher levels of uE3 than either White or Black
women (data not shown). Furthermore, sensitivity to body size would undermine the clinical
utility of uE3 as a screening tool.
High MV-O was consistently associated with decreases in BW/GA. While the presence of
maternal thrombotic lesions has been previously reported among SGAs,41 our finding was
observed in term deliveries, across the BW/GA distribution, and following adjustment for
many factors including the presence of other types of vascular pathology and maternal
hypertensive conditions. There was minimal overlap across the vascular pathology
constructs;32 thus, we believe the findings were not affected by multicollinearity. High MV-
O likely reflects significant underperfusion of the placenta which impedes nutrient, waste,
and gas exchange that supports fetal development and growth.42
The POUCH sample is demographically diverse with data on multiple biological indicators
of pregnancy health, thus providing a unique opportunity to address our study objectives.
However, there are some limitations worthy of mention. First, we employed growth
standards based upon the birthweight distributions for live births. Because growth restricted
fetuses preferentially deliver at earlier gestational ages, our operationalization of BW/GA
likely underestimates the degree of growth restriction present among preterm infants and as
such, may underestimate the contribution of preterm delivery and SGA birth to the findings
reported here.43,44 Although efforts to develop population-based intrauterine growth
standards are underway, they require further validation. Second, as illustrated by models
accounting for less than 27% of the variance in BW/GAz, the biological measures addressed
here do not represent an exhaustive list of factors that might influence birthweight and/or
long-term health outcomes. For example, original formulations of the DOHaD hypothesis
and much of the associated animal literature have identified maternal undernutrition as one
potential mechanism through which BW/GA might be associated with later disease.8,45
Although data on maternal nutritional intake are unavailable in the POUCH Study, we
employed pre-pregnancy BMI as a very rough proxy for pre-pregnancy undernutrition. We
did not use pregnancy weight gain since this measure incorporates the weight of the fetus.
(However, analyses replacing pre-pregnancy BMI with categorical or continuous measures
of pregnancy weight gain did not alter any study findings.) We recognize that pre-pregnancy
BMI is not a proxy for nutritional information, but it might identify women at risk for
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extreme under- or over-nutrition during pregnancy. Third, we assumed that missing data
(e.g. placental pathology) from a particular weighted stratum were representative of that
stratum in our adjusted analyses.
It will be important to evaluate associations among MSAFP, uE3, MV-O and health
outcomes in childhood and beyond, determining whether these indices add risk information
beyond BW/GA. This approach is consistent with recommendations by other investigators
regarding the need to identify biological mediators of long-term health outcomes.2,46,47 That
said, we recognize the limitations of the association models explored here, and though these
associations are biologically-plausible, they are not meant to imply direct causality.
Additionally, given the breadth of work investigating the contribution of maternal
malnutrition to size at birth, it will be helpful to contextualize the findings reported here
using adjusted models that include more detailed information regarding maternal diet and/or
nutritional status.
A number of interpretational caveats are also important to consider when thinking about
links between the indices of complications described here and risk for postnatal heath
outcomes. First, although our investigation centered around factors that have been
considered indicators of pathology during pregnancy, their relevance to understanding the
development of later health problems depends upon the biological plausibility of their
contributions to the particular outcome of interest. Second, attempts to link in-utero
biological measures with postnatal health problems may be undermined by the inability to
differentiate in-utero “programming” effects from genetic and postnatal environment effects
that also mediate patterns of familial risk.48,49 For example, do obstructive lesions in the
placenta (i.e., high MV-O) decrease BW/GA and alter fetal physiological systems involved
in the etiology of cardiovascular disease? Or, are these same placental lesions proxies for a
maternal thrombophilic profile that places offspring at risk for reductions in BW/GA as well
as cardiovascular disease later in life? The overarching goal of our analyses was intended to
be hypothesis-generating and was not designed to provide causal or predictive models of
BW/GA.
Our findings reinforce the idea that size at birth, including BW/GA, are composite measures
representing a myriad of influences, including those that are interpreted as innocuous (e.g.,
maternal height), helpful (e.g., adequate nutrition), or harmful (e.g., preeclampsia) to
perinatal health. Therefore, we and others argue that it is important to move beyond
measures of birth size in studies investigating the perinatal origins of adult disease and
instead identify specific exposures relevant to the long-term outcome of interest.25 Doing so
will facilitate the development of effective prevention/intervention strategies designed to
promote health during pregnancy and beyond. Nonetheless, we show that there are
meaningful biological clues about where infants fall in the BW/GA distribution beyond the
clinical diagnosis of pregnancy complications, and this may help elucidate why postnatal
health outcomes vary across the entire BW/GA continuum.5,6,50
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Table 2
Unadjusted associations between pregnancy complication indices and birth weight z-scores
Birthweight z-score
POUCH Subcohort N = 1371 POUCH Subcohort terms only N = 1036
β (95% CI) β (95% CI)
Obstetric Complications
 Hypertensive Disorders
  None (ref) --- --- --- ---
  Preeclampsia −.66* (−.95, −.38) −.67* (−1.08, −.26)
  Gestational Hypertension .22 (−.12, .57) .25 (−.13, .63)
  Chronic Hypertension −.13 (−.45, .18) −.11 (−.49, .26)
 Gestational Diabetes ( ref= None) .62* (.23, 1.00) .66* (.23, 1.09)
 Placental Abruption ( ref = None) −.18 (−.50, .15) −.11 (−.68, .46)
Maternal Serum Biomarkers
  Unexplained MSAFP ( ref = Normal) −.24* (−.39, −.10) −.26* (−.41, −.10)
  uE3 (per .5 MoM decrease) −.29* (−.39, −.19) −.28* (−.39, −.16)





 Maternal Vascular Pathology
  Obstructive (e.g., infarcts) (ref = Not High) −.63* (−.86, −.41) −.63* (−.88, −.38)
  Integrity (e.g., bleeding) (ref = Not High) .06 (−.13, .24) .06 (−.15, .27)
  Developmental (ref = Not High) −.12 (−.39, .14) −.12 (−.44, .21)
 Fetal Vascular Pathology
  Obstructive (e.g., infarcts) (ref = Not High) −.08 (−.28, .11) −.04 (−.25, .17)
  Integrity (e.g., bleeding) (ref = Not High) .11 (−.05, .26) .12 (−.05, .30)
 Histologic Chorioamnionitis
  None (ref) --- --- --- ---
  Mild −.14 (−.30, .03) −.15 (−.32, .03)




Sample sizes reflect placental samples evaluated to date.
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